74 participants
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-28
- Start Date:
- 2022-05-25
- Completion:
- 2025-05-22
Conditions
- Relapsed/ Refractory Multiple Myeloma
Interventions
- DRUG
No Results Yet